Search Press releases Keywords From To 12 Dec 2022 Changes in UCB’s Board of Directors Read More 9 Dec 2022 UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa Read More 7 Dec 2022 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis Read More 1 Dec 2022 UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care Read More 22 Nov 2022 UCB Submits Response to FDA Complete Response Letter for Bimekizumab Read More 14 Nov 2022 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients Read More Pagination First page Previous page Previous … Page 31 Page 32 Page 33 Page 34 Current page 35 Page 36 Page 37 Page 38 Page 39 … Page 35 of 61 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
